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The Clinical Pharmacogenetics Implementation Consortium 
(CPIC) Guidelines for HLA-B Genotype and Abacavir 
Dosing were originally published in April 2012. We 
reviewed recent literature and concluded that none of the 
evidence would change the therapeutic recommendations 
in the original guideline; therefore, the original publication 
remains clinically current. However, we have updated the 
Supplementary Material online and included additional 
resources for applying CPIC guidelines to the electronic 
health record. Up-to-date information can be found at 
PharmGKB (http://www.pharmgkb.org).
The Clinical Pharmacogenetics Implementation Consortium 
(CPIC) of the Pharmacogenetics Research Network (http://
www.pgrn.org) and the Pharmacogenomics Knowledge Base 
(PharmGKB, http://www.pharmgkb.org) provide peer-reviewed, 
evidence-based, freely accessible, genotype-based drug guide-
lines to help clinicians understand how available genetic test 
results could be used to optimize drug therapy.1 CPIC guidelines 
undergo continuous peer review, and information that would 
modify prescribing recommendations pertaining to gene-spe-
cific alleles and nomenclature is updated periodically on the 
PharmGKB website. Furthermore, published CPIC guidelines 
are currently systematically reviewed for updates every 2–3 
years.
The Clinical Pharmacogenetics Implementation Consortium 
Guidelines for HLA-B Genotype and Abacavir Dosing were 
originally published in April 2012.2 To update this guideline, we 
conducted a focused review of the literature published between 
April 2011 and November 2013 on HLA-B genotype and 
abacavir use (see Supplementary Material online). The minor 
allele frequency table based on ethnicity is already extensive and 
has not been updated at this time (see Supplementary Tables 
S1 and S2 online). The literature review yielded one additional 
study that we added to the evidence table in the supplementary 
material3 (see Supplementary Table S3 online). We found no 
new evidence that would change our original recommenda-
tions; therefore, the original guideline publication remains cur-
rent.2 However, recent studies have been published that further 
describe the mechanism by which abacavir can elicit an immune 
response through HLA-B*57:01. Discussion of these studies was 
added to the Supplementary Material online. Supplementary 
Figures S1 and S2 online also remain unchanged.
Recently, the CPIC Steering Committee recommended that 
authors address dosing in pediatrics in all updated and new 
CPIC guidelines. Although much of the evidence linking HLA-
B*57:01 to abacavir hypersensitivity was conducted in adults, 
there is no reason to suspect that children positive for HLA-
B*57:01 would be at less risk for abacavir hypersensitivity reac-
tions than adults positive for HLA-B*57:01. Furthermore, the 
Panel on Antiretroviral Therapy and Medical Management of 
HIV-Infected Children (Guidelines for the Use of Antiretroviral 
Agents in Pediatric HIV Infection; http://aidsinfo.nih.gov/con-
tentfiles/lvguidelines/pediatricguidelines.pdf) recommends 
against the use of abacavir in children who test positive for 
HLA-B*57:01.
CPIC guidelines are designed to help clinicians use genetic 
information to optimize drug therapy; to do this effectively, 
pharmacogenetic information must be incorporated into elec-
tronic health records (EHRs) with clinical decision support.4–6 
To provide additional resources for applying CPIC guidelines to 
the EHR, in 2013, CPIC created an informatics working group 
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focused on supporting the adoption of CPIC guidelines within 
a clinical electronic environment. This guideline is the first to 
provide these new clinical implementation resources as part of 
the Supplementary Material online, which includes workflow 
diagrams that illustrate the storage of a pharmacogenetic result 
in an EHR and the design of clinical decision support alerts 
(see Supplementary Figures S3 and S4 online). New tables 
that correspond to these workflow diagrams are provided that 
translate genotype test results into an interpreted phenotype 
(see Supplementary Tables S4–S8 online). These tables pro-
vide a summary of genotype/phenotype terms, example text for 
documentation in the EHR and point-of-care alerts, and cross-
references for drug and gene names to widely used terminolo-
gies and standardized nomenclature systems.
We recognize that each organization and EHR vendor may 
have different requirements and preferences for implementing 
pharmacogenetics within a given electronic environment. The 
intent of these resources is to synthesize foundational knowledge 
that provides a common starting point for clinical implemen-
tation so that individual organizations do not have to create a 
similar knowledge base for each new gene–drug pair for which 
pharmacogenetics is implemented. Future CPIC guidelines and 
guideline updates will provide similar resources to guide the 
implementation of gene–drug pairs in the EHR with clinical 
decision support.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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